MSI colorectal cancer, all you need to know

Clémence Flecchia(Université Paris Cité), Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Aziz Zaanan(Université Paris Cité), Gilles Manceau(Assistance Publique – Hôpitaux de Paris), Widad Lahlou(Université Paris Cité), Mehdi Karoui(Sorbonne Université), Debora Basile(University of Udine), Chloé Broudin(Assistance Publique – Hôpitaux de Paris), Lorenzo Pilla(Université Paris Cité), Claire Gallois(Université Paris Cité)
Clinics and Research in Hepatology and Gastroenterology
June 19, 2022
10.1016/j.clinre.2022.101983
Cited by 34

Related Papers

Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
|BMJ|2022|494
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
|Journal of Clinical Oncology|2020|222